Shots:
- Kelun-Biotech has reported P-III (OptiTROP-Lung05) trial data assessing sacituzumab tirumotecan (sac-TMT/SKB264/MK-2870) + Keytruda vs Keytruda monotx. as a 1L treatment for PD-L1-positive locally advanced or metastatic NSCLC with PD-L1 TPS ≥1%
- The trial met its 1EP of improved PFS, as concluded by IDMC & showed a favorable trend in the OS
- Additionally, the company is planning to engage China’s CDE on submitting an sNDA of sac-TMT for PD-L1-positive NSCLC
Ref: PRNewswire | Image: Kelun-Biotech | Press Release
Related News: China’s NMPA Approves Kelun-Biotech’s Sacituzumab Tirumotecan (sac-TMT) for EGFR-mutant NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
